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Summary
Randomised controlled trials are considered the gold standard in trial design.
However, phase II oncology trials with a binary outcome are often single-arm.
Although a number of reasons exist for choosing a single-arm trial, the pri-
mary reason is that single-arm designs require fewer participants than their
randomised equivalents. Therefore, the development of novel methodology
that makes randomised designs more efficient is of value to the trials commu-
nity. This article introduces a randomised two-arm binary outcome trial design
that includes stochastic curtailment (SC), allowing for the possibility of stop-
ping a trial before the final conclusions are known with certainty. In addition
to SC, the proposed design involves the use of a randomised block design,
which allows investigators to control the number of interim analyses. This
approach is compared with existing designs that also use early stopping,
through the use of a loss function comprised of a weighted sum of design char-
acteristics. Comparisons are also made using an example from a real trial. The
comparisons show that for many possible loss functions, the proposed design
is superior to existing designs. Further, the proposed design may be more prac-
tical, by allowing a flexible number of interim analyses. One existing design
produces superior design realisations when the anticipated response rate is
low. However, when using this design, the probability of rejecting the null
hypothesis is sensitive to misspecification of the null response rate. Therefore,
when considering randomised designs in phase II, we recommend the pro-
posed approach be preferred over other sequential designs.
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1 | INTRODUCTION
Single-arm binary outcome phase II trials require fewer participants than equivalent randomised two-arm trials, mak-
ing single-arm trials a pragmatic choice in many instances. The data from single-arm binary outcome trials are typically
compared to a pre-specified historical control response rate. However, this comparison may not be valid,1,2,3 given, for
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example, that a systematic review of phase II oncology trials found that 46% of the reviewed trials did not cite a source
for the historical response rate used.1 Two-arm randomised trials directly compare the responses of two groups from
the same population, where one group has been allocated to treatment and the other group has been allocated to con-
trol. This is preferable to a non-randomised trial comparing the responses from a contemporary population to those
from a historical population, which may differ in characteristics. Although single-arm trials are more common in small
populations and in rare disease settings, randomised designs should still be preferred when at all possible, as using his-
torical information may provide less robust evidence.4,5 Thus, it has been argued that in almost all instances, two-arm
randomised trials should be preferred to single-arm trials, with two-arm randomised trials considered to be the gold
standard in trial design.6,7 Nevertheless, single-arm trials remain popular in phase II oncology, accounting for 57% of
trials in a recent review of 557 trials.8 It is, therefore, of interest to reduce sample sizes in two-arm phase II binary out-
come trials, so that it may become possible to use two-arm designs when previously only a single-arm design would be
considered, either due to cost or recruitment difficulties. For further details on the choice of single-arm or randomised
designs, see Grayling et al.2
One approach to reducing sample size is to allow early stopping in the form of interim analyses. In the area of
single-arm trials, the most frequently implemented such design is by Simon,9 where, at a single interim analysis, the
trial may stop early due to a lack of response. An analogous two-arm design has been proposed by Jung10; as with
Simon, there is a single interim analysis and the trial may end at this point due to a lack of response. In this case, a lack
of response entails observing a low response rate on the experimental treatment arm compared to the control arm.
Further sample size savings can be made by allowing a trial to stop as soon as the final trial decision is certain,
known as non-stochastic curtailment (NSC), with respect to either a positive effect or lack of positive effect on the treat-
ment arm compared to the control arm. This can be incorporated as an extension of Jung's design,10 by additionally all-
owing the trial to stop immediately if the response rates are such that the final decision to reject or not reject the null is
known with certainty, either at the interim (to not reject only) or by the end (to either reject or not reject). This
approach was first proposed by Carsten and Chen.11 Their proposed design allows stopping after every pair of partici-
pants, where each pair is allocated evenly to experimental treatment and control, therefore assuming perfect balance.
As in Jung's design, an interim stopping boundary is used, which allows stopping only for a lack of response. “Success”
is determined for every (balanced) pair of results, where success is defined as a pair of results where response on treat-
ment and non-response on control is observed; all other combinations of results are treated equally, as a non-success.
The test statistic is then the total number of such successes. The trial stops as soon as a pre-specified required number
of successes is observed, or as soon as the number of successes required (either at the interim or at the end of the trial)
cannot be reached. The incorporation of NSC into Jung's design is also proposed by Chen et al,12 where the proposed
design allows stopping after every patient. In this design, success is determined for each patient and is defined as a
response for a participant on treatment or a non-response for a participant on control. The test statistic in this case is
the difference in the number of responses between the treatment and control arms; the same test statistic as is used by
Jung.10 The trial stops as soon as the required difference in the number of responses is guaranteed to be reached, or can-
not be reached (again, either at the interim or by the end of the trial). Thus the designs of Carsten and Chen and Chen
et al require continuous or almost continuous monitoring.11,12
We present a design approach that produces two-arm trials with expected sample sizes that are closer to those of
single-arm trials than to typical two-arm trials. This design permits early stopping of a trial not only when reaching or
failing to reach the required difference in the number of responses is certain but also when it is very likely, known as
stochastic curtailment (SC). The rationale behind SC is that when the probability of success given current results is
great, for example, 0.99, it makes sense to end that trial if a consequence is a reduction in sample size. SC has previously
been applied to single-arm trials.13,14,15 However, SC has not previously been applied to two-arm trials. Another clinical
trial characteristic that is utilised in our approach is block randomisation. In block randomisation, a block size is cho-
sen and randomisation takes place within blocks such that allocation is equal between the experimental treatment and
control arms. This places an upper bound on the degree of allocation imbalance that may occur. We introduce an
approach to designing a block randomised, two-arm binary outcome trial that uses SC, where stopping is permitted
after each block. Permitting stopping after each block is a sensible approach to early stopping, allowing trials to end
early but without the need to make a decision after every participant or pair of participants, which may be impractical
in large randomised two-arm trials. Further, the block size may be chosen to suit the resources of the trial, with smaller
block sizes allowing decisions to be made earlier and larger block sizes requiring fewer early stopping decisions. It may
be possible to undertake continuous monitoring and update a trial design after each participant.16 However, in some
circumstances, this is not possible, and the proposed design does not require such a degree of monitoring. The flexible
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framework permits a wide range of degrees of monitoring, from a small number of interim analyses to monitoring that
is almost continuous.
We note that other two-arm approaches have been proposed.17,18,19,20,21,22 However, it is impractical to compare all
randomised two-arm designs, and so our approach will be compared only to Jung's design, as this is the two-arm ana-
logue to the popular Simon design, and Carsten and Chen and Chen et al's designs, as these designs use curtailment
and as such are similar to our approach.10,11,12 Table 1 shows the main differences between the designs to be compared.
As can be seen, our approach uses a test statistic that has been used in other approaches, allows both stochastic and
NSC, allows early stopping solely based on how likely trial success is, and allows a flexible number of interim analyses.
In the Methods section, we explain the proposed approach, how design realisations are found and how the approach
will be compared to existing designs. In the Results section, our approach is compared to those of Jung, Carsten and
Chen and Chen et al.10,11,12 These comparisons are undertaken in terms of a loss function in the form of a weighted
sum of optimality criteria, as well as through sensitivity to misspecification of response rates and a real-life example.
The Discussion section puts the results into context with respect to existing designs.
2 | METHODS
For a two-arm trial, let the true response rate on the control and treatment arms be pC and pT, respectively. The nature
of hypothesis testing requires us to consider what difference in treatment effect between the two arms is worth further
study. To this end, we let p0 and p1 be the anticipated response rates in the control and treatment arms respectively,
such that the treatment difference p1 − p0 is worth further study. Our null hypothesis is as follows: H0 : pT ≤ pC.
Denoting by P(reject H0 j pC, pT) the probability that H0 is rejected given response rates pC and pT, our design will guar-
antee P(reject H0| p0, p0) ≤ α and P(reject H0 j p0, p1) ≥1 − β for specified error rates α and β.
For the proposed approach, a balanced allocation between treatment and control, that is, 1:1 randomisation, is
sought. The design involves frequent interim analyses, at most after every pair of observed results (one each on the con-
trol and treatment arms). Let N be the maximum possible total sample size and let the number of participants so far on
the control and treatment arms be mC and mT, respectively. Using randomised blocks and undertaking, an interim
analysis only at the end of each block ensures balance across the two arms at each analysis. As such, let m be the num-
ber of participants so far on each arm, for m = B, 2B, …, N/2, where 2B is the number of participants in each block. Let
XC(m) and XT(m) be the number of binary responses on the control and treatment arms after m participants on each
arm. Within each block, the number of responses on each arm follows the binomial distributions XC(B)  Binom(B, pC)
and XT(B)  Binom(B, pT), for a fixed number of participants B per block per arm. The test statistic we will use to deter-
mine whether to reject the null hypothesis is the difference in the number of responses between the arms, XT(m)
− XC(m), though other valid test statistics exist. In particular, the decision of whether to study a treatment further may
depend not solely on rejection of the null hypothesis, but also on other factors. For example, a design may explicitly
require a minimum effect size estimate before permitting further study.23,24,25 Some such methods involve sculpting of
the rejection region. However, the true response rates pC and pT may not be equal to the anticipated response rates p0
and p1, that is, the response rates may be misspecified. If so, sculpting the rejection region can lead to underestimating
the type I error.26 Sensitivity to such misspecification will be examined in the Results section and we discuss this issue
TABLE 1 Characteristics of the two-arm designs to be compared
Approach NSC SC
Early stopping for Early stopping No. stopping
Test statisticpositive treatment effect without curtailment decisions
Jung No No No Yes 2 XT − XC
Carsten and Chen Yes No Yes Yes N/2
P
I(XTi = 1, XCi = 0)
Chen et al. Yes No Yes Yes N XT − XC
Block design Yes Yes Yes No N/2B XT − XC
Note: NSC: non-stochastic curtailment; SC: stochastic curtailment; i = 1, 2, …, m, where m is the number of participants per arm so far; B:
number of participants per arm per block.
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further in the Discussion. Moreover, it is usually possible to design a trial by specifying the improvement in response
rate that would be clinically worthwhile.7
2.1 | Curtailment
At each interim analysis, there are three possible courses of action: stop the trial to make a go decision and reject the
null hypothesis; stop the trial to make a no go decision and do not reject the null hypothesis, or continue recruitment.
Define success as observing a response on the treatment arm or a non-response on the control arm, with the number of
successes in a trial so far defined as S(m) ≔ XT(m) + m − XC(m). The course of action taken is determined by compar-
ing the number of successes so far to some specified lower and upper boundaries, the calculation of which is described
below. For the final analysis, it is not possible to continue the trial further, therefore either a go or no go decision is
made and only a single boundary is required. Let this final stopping boundary be r. A go decision, that is, a decision to
reject H0, is made at an interim analysis if the final difference in number of responses is guaranteed to be r or greater in
favour of the treatment arm. This occurs at the end of the trial if XT(N/2) − XC(N/2) ≥ r or before the end of a trial if
XT(m) + m − XC(m) ≥ N/2 + r. A no go decision, that is, a decision to not reject H0, is made as soon as the final differ-
ence in responses is guaranteed to not be r or greater in favour of the treatment arm; this occurs before the end of a trial
if m − XT(m) + XC(m) ≥ N/2 − r + 1. These decision rules are the NSC boundaries used by Chen et al,12 though we
relax their requirement for continuous monitoring. Jung, Carsten and Chen and Chen et al also include an explicit
interim analysis, that is, an interim analysis at which point a go/no go decision is made regardless of whether or not
the final pre-specified stopping boundary may be reached.10,11,12 However, such an approach may result in a no go deci-
sion even when there is a high probability of correctly identifying that the null hypothesis is false. This issue has been
highlighted previously for trials using Simon's design, for example, a Simon design used in a study by Sharma et al con-
tained a no go stopping boundary at a point where the probability of correctly identifying a treatment with the desired
response rate was 0.8.15,27 Therefore, the proposed design avoids this issue by not including such an interim analysis.
While SC, a feature of our proposed design, by definition permits early stopping without knowing with certainty
whether the final stopping boundary will be reached, the proposed design quantifies at each interim the probability of
an efficacious treatment reaching the final stopping boundary. Further, lower and upper bounds for this probability can
be set by the investigator.
2.2 | Conditional power
The conditional probability, CP(pC, pT, S, m), is the probability of rejecting H0 conditional on observing S successes after
m participants on each arm assuming some response rates pC and pT, with r and N fixed. Setting pC = p0, pT = p1 gives
the conditional power CP(p0, p1, S, m). For the purposes of the proposed approach, the only conditional probability of
interest is the conditional power, and so CP(S, m) will subsequently refer solely to conditional power CP(p0, p1, S, m),
while the abbreviation CP will refer to conditional power in general. CP(S, m) is calculated using p0 and p1, that is,
there is no re-estimation of response rates. SC in this design is based on CP, though we acknowledge that other
approaches are available.28
2.2.1 | Calculating conditional power under NSC
When m − XT(m) + XC(m) ≥ N/2 − r + 1, it is no longer possible for the null hypothesis to be rejected, and so CP(S, m)
is equal to zero. Conversely, when XT(m) + m − XC(m) ≥ N/2 + r, rejection of the null hypothesis is guaranteed, and so
CP(S, m) is equal to one. For a block design with no explicit interim analysis and using NSC but not SC, CP(S, m) can
be written recursively as
CP S,mð Þ=
0, if m−XT mð Þ+XC mð Þ≥N=2−r+1
D, if m−XT mð Þ+XC mð Þ<N=2−r+1 and XT mð Þ+m−XC mð Þ<N=2+ r











P i,B j p0,p1ð ÞCP S+ i,m+Bð Þ
and P(i, B j pC, pT) = P(S(B) = i| pC, pT) = P(XT(B) + B − XC(B) = i| pC, pT), the probability of observing i successes from
a block containing B participants on each arm, given response rates pC and pT.
2.2.2 | Calculating conditional power under SC
SC entails ending a trial not only at any point where CP is equal to zero or one, but also for a no go decision at any
point where 0 < CP(S, m) < θF or for a go decision at any point where θE < CP(S, m) < 1, for fixed thresholds
(θF, θE) ∈ [0, 1] such that θF < θE. The subscripts F and E have been chosen as a no go decision is typically associated
with treatment futility and a go decision with treatment efficacy.
To incorporate SC, only slight changes to Equation (1) are required:
CP S,mð Þ=
0, ifm−XT mð Þ+XC mð Þ≥N=2−r+1orD< θF
D, ifm−XT mð Þ+XC mð Þ<N=2−r+1 and XT mð Þ+m−XC mð Þ<N=2+ r and θF ≤D≤ θE






Equations (1) and (2) are recursive as the CP at a given point, CP(S, m) say, is dependent on the CP at “future”
points CP(S + i, m + B), i = 0, 1…, 2B. Under SC (Equation (2)), CP values lower than θF are rounded down to zero and
CP values greater than θE are rounded up to one, as early stopping occurs at such points. These equations are analogous
to the calculation of CP in single-arm trials introduced by Law et al.15 Calculating CP in this manner accounts for the
possibility of early stopping due to SC. Thus it ensures that the operating characteristics are known exactly, and that
any decision to continue the trial is done so knowing exactly what degree of uncertainty remains about whether to
reject H0. By calculating the CP at each point (S, m), m = B, 2B, …, N/2, S = 0, 1, …, 2m, the stopping boundaries for the
conclusion of each block are obtained. Knowing in advance which points will, if reached, result in early stopping means
that the exact distribution of the trial's outcomes are known. Further, calculating CP without error at each point, rather
than using an approximation, prevents decisions being made based on a CP with unknown error.
Let any particular example of a trial created using our approach be characterised by (r, N, B, θF, θE, p0, p1), and
denote any such example to be a “realisation” of our design. Each design realisation has explicit lower and upper bou-
nds for CP, θF and θE, one of which must be reached before the trial may end. For existing design approaches that per-
mit early stopping to reject H0 under NSC only, such as Carsten and Chen and Chen et al, the upper bound for
rejecting the null hypothesis in terms of CP is always fixed at θE = 1.
11,12 That is, the CP must be equal to one in order
to reject the null hypothesis, and this value may not be altered. Further, the designs of Jung, Carsten and Chen and
Chen et al include an explicit interim analysis, containing some stopping boundary that does not take into account the
probability of reaching the final stopping boundary. Consequently, existing designs have no fixed lower bound θF for
ending the trial to make a no go decision; the trial is ended simply if it is no longer possible to reach the interim stop-
ping boundary. Thus for these existing designs, with regards to stopping at or prior to the interim analysis, the CP is not
evaluated and hence not known. This may lead to making a no go decision when the CP is high, as described above.
2.3 | Search for admissible designs
The paramount requirements of a design realisation are that the desired type I error α and power 1 − β are satisfied,
that is, α* = P(reject H0| p0, p0) ≤ α and 1 − β* = P(reject H0| p0, p1) ≥ 1 − β, where α* and 1 − β* are characteristics of
a given design realisation. Designs that satisfy these requirements are denoted feasible. We wish to consider only feasi-
ble designs. It is worthwhile to compare the expected sample size of feasible design realisations. Let the expected sample
size for response rates pC and pT on control and treatment arms respectively be ESS(pC, pT). Expected sample size for a
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given design is obtained by finding all possible points at which the trial will end, then multiplying the number of partic-
ipants so far at those points by the probability of reaching such points:





2jB P i, jBjpC, pTð ÞI CP i, jBð Þ∈ 0,1f gð Þ:
Our interest lies in ESS(p0, p0) and ESS(p0, p1). When searching for designs, we exclude design realisations that are
not superior to others with respect to at least one of the following criteria: expected sample size under pC = pT = p0,
ESS(p0, p0), expected sample size under pC = p0, pT = p1, ESS(p0, p1) or maximum sample size N. Such excluded designs
are termed dominated. Design realisations that are both feasible and not dominated have previously been described as
admissible designs,10,29 and these designs are our subject of interest. It is the admissible designs of our proposed
approach that will be compared, both to one another and to admissible designs of other approaches.
In order to find admissible designs, a search of possible designs is undertaken. The block size 2B, desired type I error
α and power 1 − β are specified in advance, as is an upper bound for maximum sample size, max(N), as may a range
for the final stopping boundary r. Also specified in advance are a maximum lower bound and minimum upper bound
for CP, denoted θFMAX and θEMIN , so that the design search takes place only over combinations (r, N, B, θF, θE) that satisfy
θF ≤ θFMAX and θE≥θEMIN , as per Law et al.
15 For all results that follow, θFMAX was set equal to p1, that is, a trial's CP
threshold for ending for a no go decision may not be greater than the anticipated response rate on treatment, or θF≤ p1.
This is a pragmatic choice: it is a sensible constraint to not consider a no-go decision if the current conditional probabil-
ity of trial success is greater than the probability of observing a response in a single participant allocated to a treatment
with response rate p1. A fixed value of 0.7 was chosen for θEMIN , meaning that a trial's CP threshold for ending for a go
decision may not be less than 0.7, that is, θE≥ 0.7. This value was considered a reasonable minimum probability for
making a go decision, though in practice this value may be determined in collaboration with investigators. If an investi-
gator wishes to allow early stopping for a go decision only when CP is high, then this may be set to, for example,
θEMIN =0:95, or even θEMIN =1 if an investigator wishes to permit early stopping for a go decision only when reaching
the final stopping boundary r is certain. The final value that may be specified is the maximum number of (θF, θE) com-
binations to be tested per unique (r, N). This is further explained below.
Searches were undertaken for two block sizes, 2B ∈ {2, 8}, and for five values of control arm response rate,
p0 ∈ {0.1,0.2,0.3,0.4,0.5}, with p1 = p0 + 0.2 in each instance. This resulted in 10 searches overall. These block sizes were
chosen to examine to what extent the operating characteristics change when the degree of monitoring is reduced con-
siderably. The searches had the following parameters: max(N) = 120, r ∈ {0, 1, …, dNp1e}, α = 0.15, β = 0.2 (as in table
1 of Jung10), θFMAX = p1,θEMIN =0:7 and maximum number of (θF, θE) combinations 10
6. The maximum sample size, CP
thresholds and maximum number of (θF, θE) combinations were pragmatic choices, balancing the desire to search over
as many design realisations as possible against computational intensity. Each trial, with design parameters (r, N, B, θF,
θE, p0, p1), was evaluated to obtain α
*, β*, ESS(p0, p0) and ESS(p0, p1).
2.3.1 | Searching over CP thresholds θF and θE
For any given trial design (r, N, B), each possible combination of successes, S, and participants so far, 2m, has an associ-
ated CP. As θF and θE vary, the operating characteristics of a trial are only certain to change when θF or θE become
greater than or less than one of the possible CP values in the trial. As such, we have chosen to vary θF and θE over the
trial-specific CP values rather than searching over uniform distributions of θF and θE. That is, (θF, θE) ∈ {CP(S, m)},
m = B, 2B, …, N/2, S = 0, …, 2m, s.t. θF < θE,θF ≤ θFMAX ,θE≥θEMIN .
For large sample sizes, the number of unique CP values and consequently, the number of possible (θF, θE) combina-
tions to be searched over may be great. However, certain aspects of our design approach can ameliorate this to some
degree. Firstly, in many cases, the CP is equal to zero or one. Secondly, by only permitting stopping after every 2B par-
ticipants, we need only consider the CP values that occur at the conclusion of each block, that is, after B, 2B, …, N/2 par-
ticipants on each arm. Finally, there are the user-defined limits set above: θF ≤ θFMAX , θE≥θEMIN . These three aspects
reduce the number of unique CP values for each trial design. Nevertheless, the number of possible (θF, θE) combinations
still increases rapidly with N. As such, a limit may be imposed on the maximum number of combinations that may be
examined per (r, N, B). As stated above, the limit chosen was 106, meaning that for each (r, N, B) combination, at most
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106 combinations of (θF, θE) are examined. When there are more than 10
6 possible combinations, the CP values are
ordered from smallest to greatest, then every other value is removed. This halving repeats until the number of possible
combinations remaining is not greater than 106. The same approach is undertaken in Law et al.15 As the distribution of
CP values in a trial is not uniform,15 this approach is less likely to miss potential designs than simply searching over a
uniform distribution of CP values.
Regarding searches using existing designs, admissible designs for Jung's design were found using the R package
ph2rand.10,30 Admissible designs for the designs of Carsten and Chen and Chen et al were found using simulation as
suitable code was not available: all design combinations (r1, n1, r, N) such that N ∈ [10,200], with restrictions r1 ≤ n1,
r1 ≤ r, were obtained, where r1 denotes the interim stopping boundary that must be reached after n1 participants for the
trial to continue.11,12 For each design, α* and β* were initially estimated using 100 simulated datasets. Designs with
α* > 0.25 (ie, α + 0.1) or β* > 0.3 (ie, β + 0.1) were discarded. For the remaining designs, α*, β*, ESS(p0, p0) and ESS
(p0, p1) were estimated using 10 000 simulated datasets. Designs with α
* > 0.15 or β* > 0.2 were discarded, as were
dominated designs, leaving a set of admissible designs for both approaches. To avoid confusion, the design of Carsten
and Chen will be described in the Results section as “Carsten”.11
The code to undertake the design search for the proposed design was written in R.31 It is available in the supple-
mentary material and on github.32
2.4 | The loss function
The concept of using a loss score in the form of a weighted sum of optimality criteria to compare trial designs has been
used previously.10,15,29 We use the approach of Mander et al,29 in which the loss score of a design is defined as
L=w0ESS p0,p0ð Þ+w1ESS p0,p1ð Þ+ 1−w0−w1ð ÞN ,
where w0, w1 ∈ [0, 1] and w0 + w1 ≤ 1. For all combinations of weights w0 and w1, the loss score is compared across
admissible designs from different approaches. To further compare admissible designs produced by different approaches,
we use the method of Law et al of noting the design realisation with the lowest loss score for each combination of
weights (among all design approaches).15 This design is termed the omni-admissible design. The omni-admissible
design is deemed to be the best-performing design realisation for that combination of weights. The design type of each
omni-admissible design is obtained for each combination of weights and the results plotted, to visualise what approach
performs best for each weighting of optimality criteria.
3 | RESULTS
3.1 | Comparing design approaches using multiple criteria
All results are based on the operating characteristics (α, β) = (0.15,0.20), as used in table 1 of Jung,10 and the range
p0 = 0.1, …, 0.5, p1 = p0 + 0.2. To address the case of greater response rates, a real-life example is investigated where
p0 = 0.70, p1 = 0.85.
Figure 1 shows the design approach to which the omni-admissible design belongs, that is, the design with the lowest
loss score among those compared, for all combinations of weights (w0, w1). For p0 = 0.1 and p0 = 0.2, Carsten's design
is superior in almost all instances (100% of weights for p0 = 0.1, 99% for p0 = 0.2). For p0 = 0.3, the omni-admissible
design is either a Carsten design (73%) or a block design with block size two (27%). For p0 = 0.4 and p0 = 0.5, the omni-
admissible design is either a block design with block size two or Chen's design (85% vs 15% for p0 = 0.4, 95% vs 5% for
p0 = 0.5). There are no regions for which the omni-admissible design belongs to Jung's design, as the approach of Chen
et al can be considered to produce design realisations encompassing all possible Jung design realisations but with the
addition of NSC.10,12 There are also no regions for which the omni-admissible design belongs to our approach with
block size eight, however this may be expected as any design using blocks of size eight will generally be outperformed
by the equivalent design with blocks of size two.
Figure 2 shows the difference in loss scores between the block design using block size two, existing designs and
block size eight, again for all possible weights. The difference is taken between the design realisations with the lowest
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loss scores for a given weight combination, ensuring that the best design realisation for each design approach is being
compared. As with Figure 1, the plots show that while Carsten's design is superior to the block approach for low values
of p0, it performs comparatively less well as p0 increases. This result was also found by Chen et al,
12 and can be seen
particularly on the bottom row of plots in Figure 2, where Carsten's designs perform poorly in comparison to the other
designs. The rightmost column of plots compares block size two to block size eight, and is close to white at all points,
showing that the difference between the designs is always close to zero in terms of loss score. The maximum difference
in loss score in favour of block size two compared to block size eight is six units across all combinations of weights,
compared to 61 units for block size two compared to Carsten, 25 units compared to Chen et al and 35 units compared
to Jung. An equivalent set of plots, comparing block size eight to existing designs, is shown in Figure 3, and shows simi-
lar results: both plots show the superiority of the proposed approach compared to existing designs, even when monitor-
ing is reduced to conducting an interim analysis only after each block of eight participants.
As an example of the design realisations produced by each approach, Table 2 shows a selection of design
realisations, including the Simon design, for the set of design parameters (α, β, p0, p1) = (0.15,0.20,0.30,0.50), p0 = 0.3
being the midpoint of the five values chosen for p0. For each design, the table shows the design realisations that mini-
mise ESS(p0, p0) and ESS(p0, p1) (the p0- and p1-optimal designs respectively), as well as those with the lowest ESS(p0,
p0) and ESS(p0, p1) among the designs with the minimum maximum sample size N (the p0- and p1-minimax designs,
respectively). In this case, the p0- and p1-minimax designs are identical for all designs considered. All designs that use
curtailment are superior to Jung's design in each of the criteria of interest (p0/1-optimal and p0/1-minimax).
For the p0-optimal designs, the block designs achieve lower expected sample size ESS(p0, p0) than the existing
randomised designs (47.3, 49.2 vs 64.9, 51.3, 60.1) at the expense of greater maximum sample size N (116, 112 vs 92, 88,
90). This is also the case for the p1-optimal designs with regards to ESS(p0, p1) (45.4, 49.3 vs 80.8, 52.6, 67.3, N=112,
112 vs 82, 92, 76). The Simon designs have expected sample sizes in the interval [17.0,25.1], while the standard two-arm
trial with no early stopping has expected sample size ESS(N) = N = 124. As such, ESS(p0, p0) and ESS(p0, p1) for both
block designs are closer to those of the Simon design than the two-arm sample size, under all optimality criteria.
The cases where existing two-arm designs are superior to the proposed block designs under the criterion being
minimised are the Carsten and Chen et al designs under p0/1-minimax, where these designs achieve a lower maximum
FIGURE 1 Omni-admissible design: the approach to which
the design realisation with the lowest loss score belongs, for (α,
β) = (0.15, 0.2), p0 = 0.1, 0.2, 0.3, 0.4, 0.5, p1 = p0 + 0.2
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sample size compared to the block designs (68, 76 vs 80, 80). However, the block design with block size eight requires
less monitoring than the existing designs, with a maximum of 10 decisions compared to 34 decisions for Carsten and
76 for Chen et al.11,12 These comparisons of maximum and expected sample sizes are reflected in the left-hand plots of
the third row of Figure 2, where the triangle is red near the hypotenuse, indicating superiority of the block design when
minimising expected sample size is of greatest value, and the triangle is blue near the lower left corner, indicating supe-
riority of Carsten's and Chen et al's designs when minimising maximum sample size is of greatest value.
To address possible concerns regarding very early stopping, the minimum possible number of participants was
obtained for the p0/1−optimal and p0/1−minimax block designs. The median minimum number of participants for block
size two is 9(IQR[7.5,10]) and for block size eight is 8(IQR[8, 16]). The possibility of stopping after a small number of
participants is addressed in the Discussion section.
3.2 | Misspecification of response rates
Misspecification of the response rate on treatment and/or control can lead to a probability of rejecting H0 that is consid-
erably greater or lower than expected. The consequences of such misspecification may depend on the design
approach used.
Figure 4 shows the probability of rejecting H0 when the response rates (p0, p1) are misspecified, for the p0-optimal
Carsten design and the block design with block size two under (α, β, p0, p1) = (0.15,0.20,0.10,0.30). The probability of
rejecting H0 when pT > pC is given in the lower right triangles, while the probability of rejecting H0 when pT < pC is
given in the upper left triangles. The probability of rejecting H0 when pT = pC is given by the remaining diagonal.
FIGURE 2 Difference in loss
scores for block design of size two vs
other approaches, for p0 = 0.1, ..., 0.5.
Negative values (in red) favour block
design
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Figure 5 shows the analogous probability of rejecting H0 under (α, β, p0, p1) = (0.15,0.20,0.20,0.40). The probabilities
were obtained using simulations of size 10 000. In all instances, the probability of rejecting H0 is greater using the Car-
sten design than the block design with block size two. This difference is considerable for a number of plausible pairs of
response rates. For example, in Figure 4, where the anticipated response rates are (p0, p1) = (0.1,0.3), P(reject
H0) = 0.64 using the Carsten design (vs 0.34 using the block design) when (pC, pT) = (0.3,0.3) and P(reject H0) = 0.36
(vs 0.15) when (pC, pT) = (0.3,0.2). Similarly, in Figure 5, where the anticipated response rates are (p0, p1) = (0.2,0.4),
P(reject H0) = 0.39 (vs 0.22) when (pC, pT) = (0.3,0.3), and P(reject H0) = 0.51 (vs 0.25) when (pC, pT) = (0.4,0.4). When
using Carsten's designs, if there is no difference between the treatment and control arms, and even if the treatment arm
has a poorer response rate than the control arm, there may still be a substantial probability of rejecting H0 and conclud-
ing that the treatment response rate is of clinical interest. This is of particular concern as a key advantage of
randomised trials over single-arm trials is greater accounting for response rate misspecification.6
3.3 | Example trial
A trial that has been used previously as an example in comparing two-arm binary outcome trial designs is CALGB
50502, a randomised phase II trial for the treatment of Hodgkin Lymphoma.20,22,33 The design parameters of the trial
are (α, β, p0, p1) = (0.15,0.20,0.70,0.85). Optimal designs for this set of design parameters were sought for the designs of
Jung, Carsten and Chen, Chen et al and the block designs, using the same methods as for the main comparisons.10,11,12
The maximum sample size searched over was 200, with the exception of the Carsten and Chen design, where the maxi-
mum sample size was 400. However, no feasible designs were found using the Carsten and Chen design. Table 3 shows
FIGURE 3 Difference in loss
scores for block design of size eight vs
other approaches, for p0 = 0.1, ..., 0.5.
Negative values (in red) favour block
design
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TABLE 2 p0-optimal, p1-optimal and p0/1-minimax designs, for (α, β, p0, p1) = (0.15,0.20,0.30,0.50)
r1 n1 r Narm N ESS(p0, p0) ESS(p0, p1) θF θE
p0-optimal
Simon 2 8 10 28 28 17.0 25.1 — —
Jung 0 22 5 46 92 64.9 86.7 — —
Carsten 5 19 12 44 88 51.3 60.3 0.000 1.000
Chen 0 16 5 45 90 60.1 76.9 0.000 1.000
Block 2 — — 5 58 116 47.3 47.2 0.1348 0.9831
Block 8 — — 5 56 112 49.2 49.3 0.3005 0.9700
p1-optimal
Simon 3 13 8 21 21 17.6 20.6 — —
Jung -1 28 5 41 82 70.5 80.8 — —
Carsten 9 30 10 46 92 55.0 52.6 0.000 1.000
Chen 4 35 4 38 76 63.3 67.3 0.000 1.000
Block 2 — — 6 56 112 47.9 45.4 0.1072 0.9740
Block 8 — — 5 56 112 49.2 49.3 0.3005 0.9700
p0/1-minimax
Simon 3 13 8 21 21 17.6 20.6 — —
Jung -1 28 5 41 82 70.5 80.8 — —
Carsten 4 20 10 34 68 53.3 52.9 0.000 1.000
Chen 4 35 4 38 76 63.3 67.3 0.000 1.000
Block 2 — — 4 40 80 57.3 52.7 0.0428 0.9842
Block 8 — — 4 40 80 62.2 57.1 0.0609 0.9752
Note: Narm: number of participants per arm.
FIGURE 4 Probability of rejecting H0 when (p0, p1) are misspecified, for the p0-optimal Carsten design (r1, n1, r, Narm)= (1, 3, 7, 16)
and block size two design (r, Narm, θF, θE) = (3, 31, 0.128, 0.932) under (α, β, p0, p1) = (0.15, 0.2, 0.1, 0.3)
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the p0/1-optimal and p0/1-minimax designs for the remaining designs. The p0-minimax and p1-minimax designs were
again identical. The p0- and p1-optimal block designs reduce expected sample size by approximately one third compared
to the existing designs, at the expense of increased maximum sample size. The maximum sample size for the p0/1-
minimax designs are similar across all four two-arm designs, in the range [122,128], though here ESS(p0, p0) and ESS
(p0, p1) are superior for the block designs compared to the existing designs. The Simon designs have expected sample
FIGURE 5 Probability of rejecting H0 when (p0, p1) are misspecified, for the p0-optimal Carsten design (r1, n1, r, Narm)= (2, 7, 10, 29)
and block size two design (r, Narm, θF, θE) = (5, 48, 0.115, 0.964) under (α, β, p0, p1) = (0.15, 0.2, 0.2, 0.4)
TABLE 3 p0-optimal, p1-optimal and p0/1-minimax designs, for (α, β, p0, p1)=(0.15,0.20,0.70,0.85)
r1 n1 r Narm N ESS(p0, p0) ESS(p0, p1) θF θE
p0-optimal
Simon 10 14 25 33 33 20.7 30.2 — —
Jung -1 27 6 73 146 94.6 135.1 — —
Chen 0 23 6 72 144 93.8 124.6 0.000 1.000
Block 2 — — 6 99 198 61.1 79.4 0.1108 0.9928
Block 8 — — 4 88 176 64.4 87.7 0.3391 0.9965
p1-optimal
Simon 4 7 23 30 30 21.9 28.3 — —
Jung 3 56 5 62 124 114.1 121.8 — —
Chen 1 49 6 61 122 102.9 113.2 0.000 1.000
Block 2 — — 6 99 198 61.1 79.4 0.1108 0.9928
Block 8 — — 6 92 184 66.4 83.5 0.2730 0.9866
p0/1-minimax
Simon 20 26 22 29 29 26.5 28.4 — —
Jung 3 56 5 62 124 114.1 121.8 — —
Chen 0 46 6 61 122 102.1 113.4 0.000 1.000
Block 2 — — 5 62 124 96.4 95.9 0.0064 0.9960
Block 8 — — 5 64 128 80.1 91.7 0.1304 0.9887
Note: Narm: number of participants per arm.
LAW ET AL. 223
sizes in the interval [20.7,30.2], while the standard two-arm trial with no early stopping has ESS(N) = N = 160. Again,
ESS(p0, p0) and ESS(p0, p1) for both block designs is closer to the Simon design than the two-arm design, with the
exception of the block size two design under p0/1-minimax.
4 | DISCUSSION
This manuscript introduces a new design for two-arm phase II binary outcome clinical trials. While continuous moni-
toring has previously been used in conjunction with NSC, this design is novel as it uses SC to reduce expected sample
size. Curtailment may occur due to observing either a high or low response rate on the treatment arm compared to the
control arm. Participants are allocated in a randomised block design, and trial results are noted after each block and
compared to pre-specified stopping boundaries. The trial will end if the required final difference between the arm
response rates is either certain to be reached or certain to not be reached. Additionally, the trial will end if the condi-
tional power of reaching such a state is either greater than some upper threshold θE or less than some lower threshold,
θF. These thresholds, in combination with the maximum sample size N, the required final difference in treatment arm
response rates r and desired type I error and power determine the stopping boundaries.
The probability of rejecting the null hypothesis is controlled be at most α when pC = pT = p0 and at least 1 − β when
pC = p0, pT = p1. However, if there is misspecification in the response rates, the probability of rejecting the null hypoth-
esis may be affected. This has been addressed in Section 3.2. For the proposed designs, the type I error rate is maximised
at pC = pT = 0.5, and so this error rate could be controlled over the interval [0, 1] by setting p0 = 0.5. However, this
choice may not accurately reflect an investigator's belief regarding the anticipated response rates.
The proposed block design was compared to three existing designs—those proposed by Jung, Carsten and Chen and
Chen et al.10,11,12 All three designs include an interim analysis, while the designs of Carsten and Chen and Chen et al
also use NSC.11,12 NSC is a way of permitting early stopping without the possibility of making a go/no go decision that
is different to the decision that would be made if no early stopping was permitted. However, by also including an
explicit interim analysis in addition to NSC, this certainty is somewhat negated, as a trial may stop early despite the pos-
sibility that a different decision may be made if the trial were to continue to completion, and the probability of such an
occurrence is not quantified.15 Using the proposed design, this probability is quantified and may be bounded if desired.
A comparison between the proposed design and the three existing designs was undertaken using a loss function, a
weighted sum of three optimality criteria. The type I error was set to α = 0.15 and power to 1 − β = 0.8, as in Table 1 of
Jung.10 Five sets of response rates (p0, p1) were examined. For low values of p0, only the Carsten and Chen design was
superior to the proposed block design. The superior performance of the Carsten and Chen design for low values of p0
has been previously noted by Chen et al.12 However, not discussed by Carsten and Chen nor Chen et al is sensitivity of
the Carsten and Chen design to response rate misspecification. Such misspecification can lead to a considerable
increase in the probability of rejecting H0 when the treatment is not sufficiently superior to control. For greater values
of p0, the block design is superior to the compared designs for most combinations of weights, in terms of expected and
maximum sample size, even when using blocks of size eight. Under the given requirements for type I error and power,
the expected sample size of the design with block size eight is likely to be less than or approximately equal to that
obtained using the designs of Carsten and Chen or Chen et al for p0 ≥ 0.3, and with the degree of monitoring reduced
by a factor of four or eight, respectively.
The designs were also compared using a real-life example, used previously to compare two-arm designs.10,22,33 When
minimising expected sample size under either pC = pT = p0 or pC = p0, pT = p1, the reduction in expected sample size
for the proposed block designs was considerable compared to existing designs. When minimising maximum sample
size, the proposed block designs had comparable maximum sample size and smaller expected sample size compared to
existing designs, again with monitoring frequency reduced considerably when using blocks of size eight.
The designs of Carsten and Chen and Chen et al are examples of continuous monitoring, where, in contrast to the
two-stage designs of Simon and Jung, the data are subject to more frequent interim analyses.9,10,11,12 When continuous
monitoring is used, the number of interim analyses is dependent on the number of participants' responses available,
the point at which a stopping boundary is reached and the frequency of monitoring agreed. Monitoring may take place
after every participant or less frequently.16 Continuous monitoring is of the greatest value when (tumour) response is
measured over short periods of time, though it is possible to use curtailment and continuous monitoring for response
time periods that may be considered long.34 Given the low recruitment rate of randomised controlled trials, for exam-
ple, the median rate of 0.92 participants per centre per month reported in a review by Walters et al, the effect of any lag
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on observed sample size is likely to be small.35 Further, trial recruitment rates are generally lower than expected,
favouring more frequent monitoring.15
The designs of Jung, Carsten and Chen and Chen et al use what are known are binding stopping rules, whereby
stopping is mandatory when any pre-specified stopping boundary is reached.10,11,12 This is in contrast to non-binding
stopping rules, where, despite reaching a stopping boundary, a trial may continue for other reasons, for example, to
gain more information regarding adverse events.36 Despite binding stopping rules being present, some trials have disre-
garded the planned stopping rules in practice using the same rationale as NSC, that is, the final decision is known with
certainty due to the results so far. Such curtailment has been used both due to low and high observed response rates,
and can only have been done by reviewing the results frequently.34,37,38,39,40,41 As such, some degree of continuous
monitoring is being used in some trials where none is specified.
An advantage of using the block design over existing curtailed designs is that fewer interim analyses may be
required. While Carsten and Chen's design requires monitoring after every pair of participants and Chen et al's design
after every single participant, the degree of monitoring required for the block design depends on the block size used,
and may be specified by the investigator.11,12 Further, use of larger blocks reduces computational burden with regards
to the search for design realisations, with only a small increase in expected sample size.
Our proposed design would function similarly in practice to a group sequential design with many stages. As a com-
parison, it is possible to find group sequential designs of up to 10 stages using the rpact package in R.42 Using this soft-
ware to find a design with the maximum number of stages and with the design parameters as specified as Table 2
results in a design with ESS(p0, p0) = 59.1, ESS(p0, p1) = 62.8 and N = 108 (code given in supplementary material).
These results may be compared to the proposed approach using blocks of size eight (Table 2), which finds a p0-optimal
design with ESS(p0, p0) = 49.2 (reduction of 17%), a p1-optimal design with ESS(p0, p1) = 49.3 (reduction of 21%) and a
minimax design with N = 80 (reduction of 26%). The maximum number of stages in the p0- and p1-optimal cases would
be 14 and in the minimax case would be 10, while using larger block sizes would result in fewer stages.
One limitation of the block design is that, depending on the design realisation, it is possible that a trial may end
after as few as two participants if block size two is chosen, which some investigators may not be in favour of. However,
among the set of five comparisons in the Results section, this did not occur for any of the four optimality criteria when
block size two was used. Across these design realisations, the median minimum number of participants was found to
be nine. Still, conservative investigators may prefer to either use a larger block size or to begin with a single large block
(eg, a block of size 16) before switching to a smaller block size (eg, blocks of size four), guaranteeing a minimum num-
ber of participants equal to the size of the first block. In the latter case, this would require augmenting the existing code
in order to obtain the trial operating characteristics. The block sizes used in practice may differ from the planned trial
design. In this case, the stopping boundaries could be reassessed taking this into account. Further, stopping boundaries
and conditional power could be re-estimated given the trial information so far. However, such extensions are beyond
the scope of this article.
When using randomised blocks in single-centre trials, there may be concern that investigators may engage in selec-
tion bias by successfully “guessing” the arm to which the next participant will be assigned.43 This concern is attribut-
able to simple block randomisation itself rather than the proposed trial design approach, but may still be briefly
addressed. In the first instance, we assume that any randomised study is double-blinded, that is, investigators do not
know which treatment is which.7 Selection bias may be further minimised by ensuring that the investigator responsible
for selection does not take part in participant treatment assignment. Such steps may be taken independently of the
design approach. Indeed, the CONSORT 2010 checklist of information to include when reporting a randomised trial
includes “describing any steps taken to conceal the allocation sequence until interventions were assigned.”44 A further
step that may be taken is to vary block sizes within a trial, though this would require an extension of the current work
and again is beyond the scope of this article.
If a trial uses multiple centres and the randomised blocking is stratified by centre, then some imbalance may occur.
Due to the typical size of phase II trials in oncology, we recommend using randomised blocks in a centralised system,
that is, not stratified by centre, which would ensure balance.
Regarding the timing of interim analyses, it is the case that if a number of participant results emerge in quick suc-
cession then the interim analysis may not take place at the planned information fraction. Such a possibility has not neg-
atively affected the popularity of the Simon design. As stated above, recruitment is often slow in clinical trials, with a
median recruitment rate of approximately one patient per centre per month. This reduces the possibility of observing a
cluster of concurrent results. Further, in some trials it is clear that investigators already monitor current results with
the intention of stopping due to NSC, even when such analyses are not included in the planned design.15 A stopping
LAW ET AL. 225
boundary check should be undertaken as soon as results for each complete block are available. If this is somehow not
possible and there exist excess results beyond a whole block, a stopping boundary check may still be undertaken using
the results for participants whose results constitute completed blocks. This does not affect the operating characteristics
of the design.
When using any clinical trial design that permits early stopping, the maximum likelihood estimator may be biased,
though estimators have been developed that can be used for inference in such trials.45 Examples of estimators that may
be used include the bias-adjusted estimator, the simplified bias-subtracted estimator, the median unbiased estimator
(MUE) and the uniformly minimum-variance unbiased estimator (UMVUE).46,47,48,49 These estimators have been used
in the group sequential, single arm setting to obtain point estimates and root mean squared errors.15
This article shows the benefit of using the proposed approach, which combines SC, randomised blocks and other
features in a novel way. It provides the exact distribution of a trial's outcomes, meaning that its operating characteristics
are known without sampling error. Compared to other existing two-arm designs, the proposed approach considerably
reduces expected sample size.
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